• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»wearable diagnostics

Can Heru’s PretestPro replace multiple pretesting devices in one wearable exam?

By Pallavi Madhiraju on March 13, 2026   Medical Devices & Diagnostics  

Can Heru’s PretestPro replace multiple pretesting devices in one wearable exam?

Heru’s PretestPro completes four ophthalmic pretests in under two minutes on a VR wearable. Explore what this means for clinic workflow and clinical validation. Read more.

Does WHOOP’s biomarker integration move wearables closer to regulated healthcare?

By Pallavi Madhiraju on February 12, 2026   Medical Devices & Diagnostics  

Does WHOOP’s biomarker integration move wearables closer to regulated healthcare?

WHOOP launches Advanced Labs in the UAE with Unilabs, integrating 65 biomarkers into its wearable platform. Explore what this shift means.

Will Biobeat’s wearable BP patch become the new standard in hypertension diagnosis?

By Srinath B on January 1, 2026   Medical Devices & Diagnostics  

Will Biobeat’s wearable BP patch become the new standard in hypertension diagnosis?

Biobeat raises $50M to commercialize its FDA-cleared patch-worn ABPM system. Find out how this device could change hypertension care in the U.S.

Recent Posts

  • Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity
  • AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer
  • Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?
  • Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes